Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BSEM | EFFECT | bearish | 6/10 | BioStem Technologies' S-1 registration (File No. 333-299282) became effective on October 9, 2026, enabling the company t | Oct 13, 2026 |
| HCWB | EFFECT | bearish | 6/10 | The SEC declared effective HCW Biologics' S-1 registration statement (File No. 333-299271) on October 9, 2026, enabling | Oct 13, 2026 |
| CANF | EFFECT | bearish | 5/10 | Can-Fite BioPharma's F-3 shelf registration (File No. 333-298625) became effective on October 9, 2026. This allows the c | Oct 13, 2026 |
| UPC | EFFECT | bearish | 5/10 | The SEC declared effective Universe Pharmaceuticals' F-3 shelf registration (File No. 333-299191) on October 9, 2026, en | Oct 13, 2026 |
| CANF | EFFECT | bearish | 5/10 | Can-Fite BioPharma Ltd.'s F-3 shelf registration (File No. 333-299160) became effective on October 9, 2026. This allows | Oct 13, 2026 |
| PASG | EFFECT | neutral | 3/10 | Passage BIO's registration statement on Form S-4 (File No. 333-297601) was declared effective by the SEC on October 9, 2 | Oct 13, 2026 |
| NVS | COURT-RULING | bearish | 5/10 | The D.C. District Court entered a final judgment recognizing and enforcing a foreign arbitration award against Novartis | Oct 12, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Six Twist Bioscience insiders, including the CEO, President/COO, and CFO, sold a combined $17.86M in shares over a one-w | Oct 12, 2026 |
| BIIB | ANALYST-UPGRADE | bullish | 6/10 | JP Morgan double-upgraded Biogen (BIIB) from Neutral to Overweight on October 12, 2026, raising the price target to $300 | Oct 12, 2026 |
| GSK | INST-CLUSTER | mixed | 4/10 | Institutional activity in GSK during Q2 2026 was mixed: 29 buyers added $318.7M in new positions (led by Point72 and D.E | Oct 12, 2026 |
| TERN | INST-CLUSTER | bearish | 4/10 | 52 institutional holders completely exited their positions in Terns Pharmaceuticals during Q2 2026, liquidating approxim | Oct 12, 2026 |
| EXEL | INST-CLUSTER | neutral | 3/10 | Institutional activity in EXEL during Q2 2026 was mixed: 45 buyers added $459.5M in net new holdings (led by D.E. Shaw, | Oct 12, 2026 |
| DYN | INST-CLUSTER | mixed | 4/10 | Institutional activity in Dyne Therapeutics (DYN) during Q2 2026 was mixed but skewed bullish by dollar volume: 19 buyer | Oct 12, 2026 |
| DMRA | INST-CLUSTER | neutral | 3/10 | A massive institutional cluster formed in Damora Therapeutics during Q2 2026, with 15 buyers accumulating $139.8M in net | Oct 12, 2026 |
| DNTH | INST-CLUSTER | mixed | 3/10 | Q2 2026 13F filings reveal a mixed institutional cluster in Dianthus Therapeutics (DNTH): 48 buyers added $170.9M in pos | Oct 12, 2026 |
| CGON | INST-CLUSTER | mixed | 3/10 | CG Oncology saw mixed institutional activity in Q2 2026, with 33 buyers adding $166.7M and 22 sellers reducing $129.2M. | Oct 12, 2026 |
| SYRE | INST-CLUSTER | bullish | 4/10 | A large institutional cluster in Spyre Therapeutics (SYRE) for Q2 2026 shows 49 buyers accumulating $878.2M (net +$626.7 | Oct 12, 2026 |
| RVMD | INST-CLUSTER | bullish | 4/10 | A massive institutional cluster formed in Revolution Medicines (RVMD) during Q2 2026, with 92 buyers accumulating $3.03B | Oct 12, 2026 |
| QNRX | ANALYST-UPGRADE | bullish | 4/10 | BTIG initiated coverage on Quoin Pharmaceuticals Ltd. (QNRX) with a Buy rating and a $14 price target, representing 213% | Oct 12, 2026 |
| ABT | ANALYST-UPGRADE | bullish | 4/10 | Barclays initiated coverage on ABBOTT LABORATORIES (ABT) at Overweight with a $120 price target, implying 19.9% upside f | Oct 12, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem filed a routine Form 6-K reporting treasury share holdings as of September 26, 2026. The filing confirms 27 Clas | Oct 9, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem S.A. filed a Form 6-K for October 2026, reporting insider trading activity for September 2026 under Brazilian CV | Oct 9, 2026 |
| GDTC | 6-K | bearish | 5/10 | CytoMed Therapeutics received a Nasdaq deficiency notice on October 6, 2026, for failing to maintain the $1.00 minimum b | Oct 9, 2026 |
| AVCRF | 6-K | bullish | 6/10 | Avricore Health announced that NHS England has confirmed the national expansion of the Barts Health pharmacy cholesterol | Oct 9, 2026 |
| OCGN | 144 | neutral | 2/10 | Ocugen CEO Shankar Musunuri filed a Form 144 notice of intent to sell 525,991 shares (~$498K at the filing date). The sh | Oct 9, 2026 |
| NUOX | S-1/A | neutral | 5/10 | NuvOx Therapeutics filed Amendment No. 2 to its S-1 registration statement for an IPO of 2,860,000 shares at an estimate | Oct 9, 2026 |
| RTSN | 424B4 | neutral | 5/10 | Retension Pharmaceuticals priced its IPO of 3,750,000 shares at $12.00 per share, raising gross proceeds of $45.0 millio | Oct 9, 2026 |
| GTBP | S-1 | bearish | 7/10 | GT Biopharma filed an S-1 registration statement to register up to 13,502,835 shares of common stock for resale by selli | Oct 9, 2026 |
| VNDA | SC 13G/A | neutral | 4/10 | Millennium Management LLC filed an amended Schedule 13G disclosing a 7.0% passive stake in Vanda Pharmaceuticals as of S | Oct 9, 2026 |
| GLPG | 6-K | neutral | 2/10 | Bank of America Corporation crossed below the 10% voting rights threshold in Lakefront Biotherapeutics, dropping to 8.54 | Oct 9, 2026 |